Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose-titration study of canakinumab in patients with NALP3 mutations
2004-002980-26Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Muckle-Wells syndrome (MWS) and cryopyrin-associated periodic syndrome (CAPS), sponsored by Novartis. Started Feb 2005; status: completed.
02
Drugs
canakinumab
03
Conditions
Muckle-Wells syndrome (MWS)cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2004-002980-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002980-26.